SAB Biotherapeutics (SABSW) Return on Sales (2021 - 2025)
SAB Biotherapeutics' Return on Sales history spans 5 years, with the latest figure at 238.46% for Q4 2025.
- For Q4 2025, Return on Sales rose 32515.0% year-over-year to 238.46%; the TTM value through Dec 2025 reached 198.46%, up 22315.0%, while the annual FY2024 figure was 31.72%, 1287.0% down from the prior year.
- Return on Sales reached 238.46% in Q4 2025 per SABSW's latest filing, down from 278.74% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 278.74% in Q3 2025 to a low of 86.69% in Q4 2024.
- Average Return on Sales over 5 years is 24.72%, with a median of 1.51% recorded in 2021.
- Peak YoY movement for Return on Sales: crashed -7971bps in 2023, then soared 32515bps in 2025.
- A 5-year view of Return on Sales shows it stood at 1.04% in 2021, then tumbled by -248bps to 3.63% in 2022, then crashed by -1963bps to 74.94% in 2023, then dropped by -16bps to 86.69% in 2024, then skyrocketed by 375bps to 238.46% in 2025.
- Per Business Quant, the three most recent readings for SABSW's Return on Sales are 238.46% (Q4 2025), 278.74% (Q3 2025), and 152.04% (Q2 2025).